1. Intraoperative parathyroid hormone use is high (88.3%), especially in US-trained surgeons.
2. Practice aligns with guidelines in primary hyperparathyroidism.
3. Significant variability exists in secondary and tertiary disease management.
4. Ultrasonography is the most commonly used imaging modality.
5. Workflow and cost barriers limit broader intraoperative parathyroid hormone adoption.

Source: American Journal of Otolaryngology–Head and Neck Medicine and Surgery